Global Anti-malarial Drugs Market is Projected to Surpass USD 1360.18 Million By the End of 2030 with a Growing CAGR of 4.70% | Infinium Global Research

Infinium Global Research, a leading market analysis firm, introduces a comprehensive report deciphering the global and regional dynamics of the Anti-malarial Drugs Market. This in-depth study explores market segments, drivers, restraints, and forecasts, offering a profound understanding of trends and market values.

To Know More Request a Sample of this Report: https://www.infiniumglobalresearch.com/market-reports/sample-request/291

Key Market Insights:

The global anti-malarial drugs market is valued at USD 947.67 million in 2022 and is forecasted to reach USD 1360.18 million in 2030, exhibiting a CAGR of 4.70% during the period 2023-2030.

Market Overview:

Anti-malarial drugs constitute a class of medications designed to prevent and treat malaria, a life-threatening infectious disease caused by the Plasmodium parasite transmitted through mosquito bites. These drugs target various stages of the parasite's life cycle, curbing its growth and curtailing disease progression within the human body. Malaria remains a significant global health concern, particularly in tropical regions, leading to numerous deaths annually. These medications play a pivotal role in public health and disease control, reducing transmission and serving as essential preventive measures for vulnerable populations.

Driving Forces:

The prevalence of malaria in endemic regions drives substantial demand for anti-malarial drugs, crucial in treating and preventing malaria, reducing public health impacts, and saving lives. Global awareness of malaria's severity fuels growing demand for these medications, fostering research, funding, and accessibility. However, the high cost of these drugs poses financial barriers, limiting treatment access and impeding market growth. Nevertheless, recent drug development advancements present lucrative opportunities, offering enhanced efficacy and patient outcomes.

Regional Dynamics:

The Middle East and Africa (MEA) region dominate the market due to high malaria prevalence. The UAE government initiatives and WHO interventions bolster malaria control programs in MEA. Meanwhile, the Asia-Pacific (APAC) region showcases the fastest market growth, driven by population increase, urbanization contributing to heightened malaria risks, and expanding healthcare infrastructure.

Segmentation Analysis:

The report covers drug class (quinine, chloroquine, proguanil, mefloquine, and others), route of administration (oral, injectable), and distribution channels (hospital pharmacy, retail pharmacy, e-commerce, and others), providing a comprehensive view of market diversity.

Company Profiles:

Infinium Global Research profiles key market players including Pfizer Inc., Sun Pharmaceutical Industries Ltd., Novartis AG, and others, offering insights into their market strategies and contributions.

Enquire Here Get Customization & Check the Discount for the Report @ https://www.infiniumglobalresearch.com/market-reports/customization/291

Table of Content

Chapter 1. Preface

1.1. Report Description

1.2. Research Methods

1.3. Research Approaches

Chapter 2. Executive Summary

2.1. Anti-malarial Drugs Market Highlights

2.2. Anti-malarial Drugs Market Projection

2.3. Anti-malarial Drugs Market Regional Highlights

Chapter 3. Global Anti-malarial Drugs Market Overview

3.1. Introduction

3.2. Market Dynamics

3.2.1. Drivers

3.2.2. Restraints

3.2.3. Opportunities

3.3. Porter`s Five Forces Analysis

3.4. IGR-Growth Matrix Analysis

3.4.1. IGR-Growth Matrix Analysis by Drug Class

3.4.2. IGR-Growth Matrix Analysis by Route of Administration

3.4.3. IGR-Growth Matrix Analysis by Distribution Channel

3.4.4. IGR-Growth Matrix Analysis by Region

3.5. Value Chain Analysis of Anti-malarial Drugs Market

Chapter 4. Anti-malarial Drugs Market Macro Indicator Analysis

Chapter 5. Company Profiles and Competitive Landscape

5.1. Competitive Landscape in the Global Anti-malarial Drugs Market

5.2. Companies Profiles

5.2.1. Pfizer Inc.

5.2.2. weefselpharma.com.

5.2.3. Sun Pharmaceutical Industries Ltd.

5.2.4. Alvizia Health Care

5.2.5. Actiza Pharmaceutical Private Limited

5.2.6. Novartis AG

5.2.7. GSK plc.

5.2.8. Bayer AG

5.2.9. Ipca Laboratories Ltd.

5.2.10. Merck & Co., Inc.

Chapter 6. Global Anti-malarial Drugs Market by Drug Class

6.1. Quinine

6.2. Chloroquine

6.3. Proguanil

6.4. Mefloquine

6.5. Others

Chapter 7. Global Anti-malarial Drugs Market by Route of Administration

7.1. Oral

7.2. Injectable

Chapter 8. Global Anti-malarial Drugs Market by Distribution Channel

8.1. Hospital Pharmacy

8.2. Retail Pharmacy

8.3. E-commerce

8.4. Others

Chapter 9. Global Anti-malarial Drugs Market by Region 2023-2030

9.1. North America

9.1.1. North America Anti-malarial Drugs Market by Drug Class

9.1.2. North America Anti-malarial Drugs Market by Route of Administration

9.1.3. North America Anti-malarial Drugs Market by Distribution Channel

9.1.4. North America Anti-malarial Drugs Market by Country

9.1.4.1. The U.S. Anti-malarial Drugs Market

9.1.4.1.1. The U.S. Anti-malarial Drugs Market by Drug Class

9.1.4.1.2. The U.S. Anti-malarial Drugs Market by Route of Administration

9.1.4.1.3. The U.S. Anti-malarial Drugs Market by Distribution Channel

9.1.4.2. Canada Anti-malarial Drugs Market

9.1.4.2.1. Canada Anti-malarial Drugs Market by Drug Class

9.1.4.2.2. Canada Anti-malarial Drugs Market by Route of Administration

9.1.4.2.3. Canada Anti-malarial Drugs Market by Distribution Channel

9.1.4.3. Mexico Anti-malarial Drugs Market

9.1.4.3.1. Mexico Anti-malarial Drugs Market by Drug Class

9.1.4.3.2. Mexico Anti-malarial Drugs Market by Route of Administration

9.1.4.3.3. Mexico Anti-malarial Drugs Market by Distribution Channel

9.2. Europe

9.2.1. Europe Anti-malarial Drugs Market by Drug Class

9.2.2. Europe Anti-malarial Drugs Market by Route of Administration

9.2.3. Europe Anti-malarial Drugs Market by Distribution Channel

9.2.4. Europe Anti-malarial Drugs Market by Country

9.2.4.1. Germany Anti-malarial Drugs Market

9.2.4.1.1. Germany Anti-malarial Drugs Market by Drug Class

9.2.4.1.2. Germany Anti-malarial Drugs Market by Route of Administration

9.2.4.1.3. Germany Anti-malarial Drugs Market by Distribution Channel

9.2.4.2. United Kingdom Anti-malarial Drugs Market

9.2.4.2.1. United Kingdom Anti-malarial Drugs Market by Drug Class

9.2.4.2.2. United Kingdom Anti-malarial Drugs Market by Route of Administration

9.2.4.2.3. United Kingdom Anti-malarial Drugs Market by Distribution Channel

9.2.4.3. France Anti-malarial Drugs Market

9.2.4.3.1. France Anti-malarial Drugs Market by Drug Class

9.2.4.3.2. France Anti-malarial Drugs Market by Route of Administration

9.2.4.3.3. France Anti-malarial Drugs Market by Distribution Channel

9.2.4.4. Italy Anti-malarial Drugs Market

9.2.4.4.1. Italy Anti-malarial Drugs Market by Drug Class

9.2.4.4.2. Italy Anti-malarial Drugs Market by Route of Administration

9.2.4.4.3. Italy Anti-malarial Drugs Market by Distribution Channel

9.2.4.5. Rest of Europe Anti-malarial Drugs Market

9.2.4.5.1. Rest of Europe Anti-malarial Drugs Market by Drug Class

9.2.4.5.2. Rest of Europe Anti-malarial Drugs Market by Route of Administration

9.2.4.5.3. Rest of Europe Anti-malarial Drugs Market by Distribution Channel

9.3. Asia Pacific

9.3.1. Asia Pacific Anti-malarial Drugs Market by Drug Class

9.3.2. Asia Pacific Anti-malarial Drugs Market by Route of Administration

9.3.3. Asia Pacific Anti-malarial Drugs Market by Distribution Channel

9.3.4. Asia Pacific Anti-malarial Drugs Market by Country

9.3.4.1. China Anti-malarial Drugs Market

9.3.4.1.1. China Anti-malarial Drugs Market by Drug Class

9.3.4.1.2. China Anti-malarial Drugs Market by Route of Administration

9.3.4.1.3. China Anti-malarial Drugs Market by Distribution Channel

9.3.4.2. Japan Anti-malarial Drugs Market

9.3.4.2.1. Japan Anti-malarial Drugs Market by Drug Class

9.3.4.2.2. Japan Anti-malarial Drugs Market by Route of Administration

9.3.4.2.3. Japan Anti-malarial Drugs Market by Distribution Channel

9.3.4.3. India Anti-malarial Drugs Market

9.3.4.3.1. India Anti-malarial Drugs Market by Drug Class

9.3.4.3.2. India Anti-malarial Drugs Market by Route of Administration

9.3.4.3.3. India Anti-malarial Drugs Market by Distribution Channel

9.3.4.4. South Korea Anti-malarial Drugs Market

9.3.4.4.1. South Korea Anti-malarial Drugs Market by Drug Class

9.3.4.4.2. South Korea Anti-malarial Drugs Market by Route of Administration

9.3.4.4.3. South Korea Anti-malarial Drugs Market by Distribution Channel

9.3.4.5. Australia Anti-malarial Drugs Market

9.3.4.5.1. Australia Anti-malarial Drugs Market by Drug Class

9.3.4.5.2. Australia Anti-malarial Drugs Market by Route of Administration

9.3.4.5.3. Australia Anti-malarial Drugs Market by Distribution Channel

9.3.4.6. Rest of Asia-Pacific Anti-malarial Drugs Market

9.3.4.6.1. Rest of Asia-Pacific Anti-malarial Drugs Market by Drug Class

9.3.4.6.2. Rest of Asia-Pacific Anti-malarial Drugs Market by Route of Administration

9.3.4.6.3. Rest of Asia-Pacific Anti-malarial Drugs Market by Distribution Channel

9.4. RoW

9.4.1. RoW Anti-malarial Drugs Market by Drug Class

9.4.2. RoW Anti-malarial Drugs Market by Route of Administration

9.4.3. RoW Anti-malarial Drugs Market by Distribution Channel

9.4.4. RoW Anti-malarial Drugs Market by Sub-region

9.4.4.1. Latin America Anti-malarial Drugs Market

9.4.4.1.1. Latin America Anti-malarial Drugs Market by Drug Class

9.4.4.1.2. Latin America Anti-malarial Drugs Market by Route of Administration

9.4.4.1.3. Latin America Anti-malarial Drugs Market by Distribution Channel

9.4.4.2. Middle East Anti-malarial Drugs Market

9.4.4.2.1. Middle East Anti-malarial Drugs Market by Drug Class

9.4.4.2.2. Middle East Anti-malarial Drugs Market by Route of Administration

9.4.4.2.3. Middle East Anti-malarial Drugs Market by Distribution Channel

9.4.4.3. Africa Anti-malarial Drugs Market

9.4.4.3.1. Africa Anti-malarial Drugs Market by Drug Class

9.4.4.3.2. Africa Anti-malarial Drugs Market by Route of Administration

9.4.4.3.3. Africa Anti-malarial Drugs Market by Distribution Channel

More Insights on this report, Speak to Our Analyst: https://www.infiniumglobalresearch.com/market-reports/enquiry/291

Reasons to Buy this Report:

=> Comprehensive analysis of global as well as regional markets of anti-malarial drugs.

=> Complete coverage of all the product types and application segments to analyze the trends, developments, and forecast of market size up to 2030.

=> Comprehensive analysis of the companies operating in this market. The company profile includes an analysis of the product portfolio, revenue, SWOT analysis, and the latest developments of the company.

=> Infinium Global Research- Growth Matrix presents an analysis of the product segments and geographies that market players should focus on to invest, consolidate, expand, and/or diversify.

2nd Floor, Ganadish Empire, Rahatani Chowk, Pimple Saudagar, Pimpri-Chinchwad, Maharashtra 411027

About Infinium Global Research:

Infinium Global Research is a business consulting and market research firm; a group of experts that caters to fulfilling business and market research needs of leading companies in various industry verticals and business segments. The company also serves government bodies, institutes, and non-profit/non-government organizations to meet their knowledge and information needs.

Through our information services and solutions, we assist our clients to improve their performance and assess the market conditions to achieve their organizational goals. Our team of experts and analysts are engaged in continuously monitoring and assessing the market conditions to provide knowledge support to our clients. To help our clients and to stay updated with the advances and inventions in technology, business processes, regulations, and the environment, Infinium often conducts regular meets with industry experts and opinion leaders. Our key opinion leaders are involved in monitoring and assessing the progress in the business environment, so as to offer the best opinion to our clients.

This release was published on openPR.